Mario Gomez Delgado de la Flor, MD
Pulmonary Disease · Weslaco, TXNPI 1093804189
Payments from drug & device makers
Across 8 payments — averaging $61.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$141
- AbbVie$140
- Actelion Pharmaceuticals US, Inc.$98
- Fisher & Paykel Healthcare Inc$71
- Philips North America LLC$14
- Paratek Pharmaceuticals, Inc.$14
- plus $13 from 1 others
What the payments were for
- Food & beverage$491100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 1 | $141 |
| AbbVie | 1 | $140 |
| Actelion Pharmaceuticals US, Inc. | 1 | $98 |
| Fisher & Paykel Healthcare Inc | 2 | $71 |
| Philips North America LLC | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ILLUMISITE$141
- AVYCAZ$140
How this compares
$491 in reported general payments places this provider in the 25th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 87 | $1,094,718 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 411 | $320,466 |
| Breo ElliptaFluticasone/Vilanterol | 422 | $184,126 |
| Dupixent PenDupilumab | 26 | $94,393 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 111 | $59,393 |
| Incruse ElliptaUmeclidinium Bromide | 75 | $27,716 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $16,476 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 571 | $15,205 |
| EliquisApixaban | 23 | $13,839 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 71 | $12,758 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 27 | $12,679 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 33 | $12,356 |
| Spiriva RespimatTiotropium Bromide | 17 | $10,792 |
| SymbicortBudesonide/Formoterol Fumarate | 30 | $6,407 |
| Montelukast Sodium | 472 | $4,107 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Weslaco
- Alfredo Renzo Arauco BrownWeslaco$817K
- Charles AndrewsSan Antonio$17M
- Ivan RosasHouston$13.8M
- Shahrukh KureishyMcKinney$12.4M
- Raksha JainDallas$3.4M
- Kelly ChinDallas$2.7M
- Julie PhilleyTyler$2.4M
- Nicola HananiaHouston$2.2M
- Sandeep SahayHouston$2.1M
- Antonio AnzuetoSan Antonio$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.